Dova Pharmaceuticals
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$5.3M
Doctors Paid
4,583
Transactions
10,998
2021 Total
$1.4M
Payment Breakdown by Category
Research$2.3M (43.5%)
Consulting$789,398 (15.0%)
Food & Beverage$272,270 (5.2%)
Travel$153,035 (2.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 379 | 43.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 549 | 32.5% |
| Consulting Fee | $789,398 | 301 | 15.0% |
| Food and Beverage | $272,270 | 9,163 | 5.2% |
| Travel and Lodging | $153,035 | 476 | 2.9% |
| Space rental or facility fees (teaching hospital only) | $33,200 | 10 | 0.6% |
| Grant | $14,000 | 3 | 0.3% |
| Education | $1,332 | 117 | 0.0% |
Payments by Type
General
$3.0M
10,619 transactions
Research
$2.3M
379 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A 3-period, 2-sequence, Randomized, Open-label, Partial Replicate Study to Evaluate the Bioequivalence of 2 Lots of Avatrombopag 20 mg Oral Tablets (Test and Reference) Administered as a Single Dose in Healthy Adult Subjects under the Fed Condition | $674,854 | 0 | 1 |
| Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. | $372,999 | 1 | 152 |
| A Single-dose, Six-sequence Cross-over Study to Compare the Relative Oral Bioavailability of and Food Effect on a Pediatric Age-Appropriate Avatrombopag Formulation Compared to the Commercial Tablet Formulation in Healthy Adult Subjects Under Fed and Fasted Conditions. | $353,975 | 0 | 2 |
| Randomized, Double-blind, Placebo-controlled Study With Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for greater than or equal to 6 Months | $346,492 | 0 | 29 |
| Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer. | $201,615 | 0 | 44 |
| An Observational Cohort Study of the Use of Avatrombopag in Patients With Thrombocytopenia Associated With Chronic Liver Disease Undergoing a Procedure | $110,148 | 0 | 22 |
| An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects with Thrombocytopenia Scheduled for a Surgical Procedure | $96,449 | 0 | 41 |
| Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim | $90,208 | 0 | 68 |
| Open-label multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding | $41,597 | 0 | 20 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Nashat Gabrail, M.d, M.D | Specialist | Canton, OH | $173,118 | $0 |
| Dr. Steven Fein, M.d, M.D | Hematology & Oncology | Miami, FL | $106,727 | $0 |
| Dr. Moshe Levy, Md, MD | Medical Oncology | Dallas, TX | $105,543 | $0 |
| Hillary Maitland, M.d, M.D | Student in an Organized Health Care Education/Training Program | Charlottesville, VA | $104,483 | $0 |
| Dr. Siamak Saadat, M.d, M.D | Internal Medicine | Colton, CA | $83,946 | $0 |
| Sammy Saab, Md, MD | Transplant Surgery | Los Angeles, CA | $74,636 | $0 |
| Srikanth Nagalla, Md, MD | Hematology & Oncology | Miami, FL | $62,514 | $0 |
| Wajahat Khan, Md, MD | Medical Oncology | Grosse Pointe Woods, MI | $55,221 | $0 |
| Ralph Boccia, M.d, M.D | Medical Oncology | Bethesda, MD | $54,384 | $0 |
| Tarek Chidiac, Md, MD | Medical Oncology | Columbus, OH | $53,892 | $0 |
| Anthony Botti, M.d, M.D | Hematology & Oncology | Livingston, NJ | $52,501 | $0 |
| Dr. Yousuf Gaffar, Md, MD | Hematology & Oncology | Denver, CO | $49,443 | $0 |
| Mr. Ruemu Birhiray, Md, MD | Hematology & Oncology | Indianapolis, IN | $44,986 | $0 |
| Hanny Al-Samkari, Md, MD | Hematology & Oncology | Boston, MA | $39,441 | $0 |
| Dr. Caroline Piatek, M.d,, M.D, | Internal Medicine | Los Angeles, CA | $38,568 | $0 |
| James Bussel, Md, MD | Pediatrics | New York, NY | $38,382 | $0 |
| Dr. Rajesh Kukunoor, M.d, M.D | Hematology & Oncology | Scottsdale, AZ | $36,649 | $0 |
| Keith Mccrae, Md, MD | Hematology & Oncology | Cleveland, OH | $33,859 | $0 |
| Dr. Ilan Weisberg, M.d, M.D | Gastroenterology | New York, NY | $30,821 | $0 |
| Alfredo Torres Gonzalez, M.d, M.D | Hematology & Oncology | Port Jefferson Station, NY | $30,573 | $0 |
| Dr. Edgardo Santos, Md, MD | Hematology & Oncology | Fort Lauderdale, FL | $28,996 | $0 |
| Dr. Michael Tarantino, Md, MD | Pediatric Hematology-Oncology | Peoria, IL | $28,745 | $0 |
| Dr. Jeffrey Crippin, Md, MD | Gastroenterology | Saint Louis, MO | $27,700 | $0 |
| Dr. Shail Dalal, Md, MD | Hematology & Oncology | Palestine, TX | $27,235 | $0 |
| Dr. John Winters, Md, MD | Hematology & Oncology | Westbrook, ME | $27,023 | $0 |
About Dova Pharmaceuticals
Dova Pharmaceuticals has made $5.3M in payments to 4,583 healthcare providers, recorded across 10,998 transactions in the CMS Open Payments database. In 2021, the company paid $1.4M. The top product by payment volume is Doptelet ($5.3M).
Payments were distributed across 101 medical specialties. The top specialty by payment amount is Hematology & Oncology ($918,443 to 1,177 doctors).
Payment categories include: Food & Beverage ($272,270), Consulting ($789,398), Research ($2.3M), Travel & Lodging ($153,035).
Dova Pharmaceuticals is associated with 1 products in the CMS Open Payments database.